Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024

Rhea-AI Summary

Acurx Pharmaceuticals (NASDAQ: ACXP), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, has announced that it will discuss its third quarter 2024 financial results on Wednesday, November 13, 2024, at 8:00 am ET before the U.S. financial markets open. The company's President and CEO, David P. Luci, along with CFO Robert G. Shawah, will host a conference call to discuss the results and provide a business update.

Interested parties can join the call using the following details:
- Toll-free (U.S.): 877-790-1503
- International: Participant international Toll-Free access numbers available via provided link
- Conference ID: 13749688

STATEN ISLAND, N.Y., Oct. 16, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late- stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its third quarter 2024 financial results on Wednesday, November 13, 2024 at 8:00 am ET before the U.S. financial markets open.

David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:

Date:	Wednesday, November 13, 2024
Time:	8:00 a.m. ET
Toll free (U.S.):	877-790-1503
International:	Click here for participant international Toll-Free access numbers
https://www.incommconferencing.com/international-dial-in
Conference ID:	13749688

About Ibezapolstat

Ibezapolstat is the Company's lead antibiotic candidate preparing to advance to international Phase 3 clinical trials to treat patients with C. difficile Infection (CDI).  Ibezapolstat is a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS^®) antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections. Ibezapolstat's unique spectrum of activity, which includes C. difficile but spares other Firmicutes and the important Actinobacteria phyla, appears to contribute to the maintenance of a healthy gut microbiome.

In June 2018, ibezapolstat was designated by the U.S. Food and Drug Administration (FDA) as a Qualified Infectious Disease Product (QIDP) for the treatment of patients with CDI and will be eligible to benefit from the incentives for the development of new antibiotics established under the Generating New Antibiotic Incentives Now (GAIN) Act. In January 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI. The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI.

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP).

To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com. 

Forward-Looking Statements 

Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2023, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward- looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.

Investor Contact:

Acurx Pharmaceuticals, Inc.

David P. Luci, President & CEO

Tel:  917-533-1469

Email:  davidluci@acurxpharma.com 

View original content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-to-discuss-third-quarter-2024-financial-results-on-november-13-2024-302277353.html

SOURCE Acurx Pharmaceuticals, Inc.

FAQ

When will Acurx Pharmaceuticals (ACXP) release its Q3 2024 financial results?

Acurx Pharmaceuticals (ACXP) will release its third quarter 2024 financial results on Wednesday, November 13, 2024, before the U.S. financial markets open.

What time is the Acurx Pharmaceuticals (ACXP) Q3 2024 earnings call scheduled for?

The Acurx Pharmaceuticals (ACXP) Q3 2024 earnings call is scheduled for Wednesday, November 13, 2024, at 8:00 am ET.

Who will host the Acurx Pharmaceuticals (ACXP) Q3 2024 earnings call?

The Acurx Pharmaceuticals (ACXP) Q3 2024 earnings call will be hosted by David P. Luci, President and CEO, and Robert G. Shawah, CFO.

What is the conference ID for Acurx Pharmaceuticals' (ACXP) Q3 2024 earnings call?

The conference ID for Acurx Pharmaceuticals' (ACXP) Q3 2024 earnings call is 13749688.